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Abstract
Background: The voltage-gated potassium channel hEag1 (KV10.1) has been related to cancer biology. The
physiological expression of the human channel is restricted to the brain but it is frequently and abundantly
expressed in many solid tumors, thereby making it a promising target for a specific diagnosis and therapy. Because
chronic lymphatic leukemia has been described not to express hEag1, it has been assumed that the channel is not
expressed in hematopoietic neoplasms in general.
Results: Here we show that this assumption is not correct, because the channel is up-regulated in myelodysplastic
syndromes, chronic myeloid leukemia and almost half of the tested acute myeloid leukemias in a subtype-
dependent fashion. Most interestingly, channel expression strongly correlated with increasing age, higher relapse
rates and a significantly shorter overall survival. Multivariate Cox regression analysis revealed hEag1 expression
levels in AML as an independent predictive factor for reduced disease-free and overall survival; such an association
had not been reported before. As a functional correlate, specific hEag1 blockade inhibited the proliferation and
migration of several AML cell lines and primary cultured AML cells in vitro.
Conclusion: Our observations implicate hEag1 as novel target for diagnostic, prognostic and/or therapeutic
approaches in AML.
Background
Acute myeloid leukemia (AML), characterized by
strong proliferation of undifferentiated hematopoietic
progenitor cells, is the most common type of acute
leukemia in adults. AML subtypes are very heteroge-
neous, with different chromosomal aberrations, thera-
peutic response and outcome. Age and certain
chromosomal aberrations are markers for a good or
bad prognosis, but 45% of AML have a normal karyo-
type and an unclear intermediate prognosis with a
five-year survival rate of only 40% [1]. Prognosis fac-
tors are crucial for therapy decisions like bone marrow
transplantations, which can cure the disease but are
not devoid of severe side effects. An increasing number
of genetic parameters (mainly gene mutations impli-
cated in hematopoietic differentiation or transcription
regulation) are being identified as predictive factors.
Examples are FLT3-ITD (Internal Tandem Duplication
of Receptor Tyrosine Kinase) or partial tandem dupli-
cations of the MLL gene (Mixed Lineage Leukemia),
which are associated with a poor prognosis [2,3].
Therapies against certain subtypes with distinct biolo-
gical features offer noticeably improved outcome, as
established for AML M3 with 90% survival, highlight-
ing the need for specific therapeutic regimes [4].
Increasing evidence relates ion channels to cancer
pathogenesis and prompts their use in diagnosis and
therapy [5]. Voltage-gated K+-channels show the highest
variability among ion channels with over 70 genes. The
channels expressed in a given cell are specific not only
for the cell type but also for its physiological status.
These channels represent a suitable distinctive element
for both healthy and tumor cells and have aroused sig-
nificant interest in cancer research [5-7]. Our group is
specifically interested in the human voltage-gated potas-
sium ion channel ether à go-go 1 (hEag1) because of its
pathological expression in tumor cells and its potentially
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oncogenic properties [8-13]. The physiological expres-
sion of hEag1 is largely restricted to the brain where its
role is still unknown [14], although transient hEag1
expression induces myoblast fusion and exit from the
cell cycle during myoblast differentiation [15]. hEag1
expression and functional characteristics are modulated
in neuronal cells throughout the cell cycle [16] and by
many factors like the cytoskeleton or calmodulin [8,17].
During neuroblastoma differentiation, hEag1 expression
is strongly down-regulated [18].
Non-neural cells aberrantly overexpressing hEag1
acquire phenotypical characteristics of malignancy and
induce aggressive tumor growth in immunodeficient
SCID mice [12]. hEag1 is significantly overexpressed in
many tumor cell lines and more than 75% primary solid
tumors from different histological origins like breast,
colon or cervix carcinomas [10,19] and sarcomas [11].
Importantly, the channel cannot be detected in the ori-
ginating normal tissues. hEag1 inhibition by the antihis-
tamine astemizole, the tricyclic antidepressant
imipramine or hEag1 specific monoclonal antibodies
reduces tumor cell proliferation in vitro and in vivo
[9,11,20-23]. In summary, the expression of hEag1 in
many solid tumors is clearly established though its func-
tional role in carcinogenesis or tumor maintenance is
still under investigation.
In chronic lymphatic leukemias the related channel
HERG (human Eag-related gene, KV11.1) could be iden-
tified, but no hEag1 expression was detected [24]; it was
subsequently assumed that hEag1 had no relevant role
in leukemias.
Leukemias and lymphomas are an important and fre-
quent group of tumors with very distinct pathophysio-
logical features in contrast to solid tumors. The goal of
the current study was to determine if different types of
leukemias share the biological feature of solid tumors
to express hEag1. Additionally, we wanted to deter-
mine if any potential expression might have functional
correlates or even prognostic value. Within leukemias
we focused on AML and analyzed hEag1 expression by
quantitative real-time PCR (qPCR) and correlated it to
several patient characteristics. A possible role of hEag1
in leukemia cell proliferation could be shown by
growth and migration inhibition of the hEag1-expres-
sing cell lines PLB-985, K562, UT-7 and HEL and pri-
mary clinical samples by the potassium channel
blockers astemizole, imipramine, the hEag1 specific
monoclonal antibody mAb56 and siRNA knockdown
[9]. No involvement of hEag1 expression during HL-60
cell differentiation was detected. Cell cycle related
changes and apoptosis induction were analyzed to
determine possible inhibitor effects useful for any
hEag1-based therapy.
Results
hEag1 is frequently expressed in primary myeloid
leukemias and leukemia cell lines
As the expression of the hEag1 channel in leukemias is
unknown our aim was to study the prevalence of hEag1
in different kinds of leukemias.
We determined hEag1 expression in 181 blood or
bone marrow samples derived from patients with hema-
tological disorders, including AML, ALL, CML and
MDS. Samples with low RNA content (n = 12) or lack-
ing clinical data (n = 15) were excluded from the study.
Finally, hEag1 expression was analyzed in 154 samples
by qPCR. The results are summarized in Fig. 1 and
Table 1. We confirmed that healthy peripheral blood
cells do not show detectable hEag1 expression (n = 10).
Acute lymphoblastic leukemia (ALL) (n = 8) and
biphenotypic acute leukemia (n = 3) were hEag1-nega-
tive in all samples analyzed.
hEag1 was detected in 5 of 13 cases (38%) of chronic
myeloid leukemia (CML), and interestingly, 58% of the
samples with myelodysplastic syndrome (MDS; n = 12)
expressed hEag1. Many MDS progress into AML, but
inducing factors and time until progression are still
unknown. One hEag1 positive patient with MDS pro-
gressed quickly after two months into an AML M2,
another patient died after five months. Two other
patients with hEag1 positive MDS were followed for
more than one year and two patients for more than two
years without any progression. We further followed one
patient with AML M4 that was hEag1 positive at first
diagnosis. After 14 months, a relapse occurred and the
amount of hEag1 expression was strongly increased.
40% of the analyzed AML samples expressed hEag1
(47 of 118 samples). According to the FAB (French-
American-British) classification, a subtype-dependent
expression pattern was observed: AML FAB M3 (n = 8)
and M4Eo (n = 6) were consistently hEag1-negative.
Within the other subgroups, hEag1 was expressed in 2
of 7 M0 (28%), 9 of 20 M1 (45%), 3 of 14 M5 (21%), 3
of 5 M6 (60%) and 1 of 3 M7 cases (33%). The most
common subtypes M2 and M4 frequently expressed
hEag1 (14 of 25 cases (56%) and 10 of 19 cases (53%),
respectively) (Fig. 1).
hEag1 expression was also tested by real-time PCR in
HL-60, UT-7, K562, PLB-985, HEL, KASUMI and CMK
cell lines. hEag1 RNA was detected in K562, PLB-985,
UT-7, HL-60 and HEL cells. Primary cells were obtained
from the peripheral blood of four AML patients, and
hEag1 expression was detected in two of them (P3 and
P4, Fig. 2A).
In order to establish specificity of the hEag1 inhibitor
effects during proliferation assays, we also determined
the expression of HERG (KV11.1) in the hEag1 positive
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cell lines. UT-7 cells expressed equal and K562 cells
higher levels of HERG channels compared to hEag1,
whereas we did not detect HERG in PLB-985, HL-60 or
HEL cells. All four patient samples were negative for
HERG expression.
Protein expression was confirmed by flow cytometry
using an anti-hEag1 specific monoclonal antibody
(mAb49) directed against an extracellular loop of the
channel. The results are summarized in Fig. 2B. Some
background fluorescence was detected in all cell lines,
including hEag1-negative patient samples. For this rea-
son, we subtracted the magnitude of the mean fluores-
cence intensity (MFI) shift observed in Patient 2 cells
(hEag1 negative in PCR) from all measurements. Under
these conditions, hEag1 knockdown by siRNA in PLB-
985 and K562 cells completely abolished the increase in
fluorescence intensity (Fig. 2C), indicating that the MFI
shift is due to hEag1 protein expression.
The hEag1 channel is indeed expressed in several cell
lines and primary clinical specimens of newly diagnosed
myeloid leukemias.
hEag1 expression in AML is subtype-dependent and
correlates with increasing age
Broad statistical analyses were performed for AML
because of the relatively high number of samples avail-
able. There was no significant correlation between
hEag1 expression and initial laboratory parameters
such as platelet counts (median, 58 vs. 54 × 109/l; p =
0.62), LDH (511 vs. 451 U/L; p = 0.24), hemoglobin
(9.5 vs. 8.8 g/dL; p = 0.36), peripheral blood blasts (42
vs. 66%; p = 0.39) and bone marrow blasts (90 vs. 85%;
p = 0.94). White blood cell counts were higher in
hEag1 expressing samples without reaching statistical
significance (median, 50.8 vs.32 × 109/L; p = 0.76).
There was also no difference in gender distribution
between hEag1 positive and hEag1 negative patients (p
= 1.0).
hEag1 expression was significantly more frequent in
older patients (median 60 vs. 31 years, p = <0.001). 13%
of AML in children (up to 18 years; n = 37) but 47% of
adults (19-59 years; n = 38) and 53% of patients above
the age of 60 years (n = 43) were hEag1 positive (Fig. 3).
Three prognostic groups can be defined in AML
according to cytogenetic aberrations. The favorable
group is defined by t(8;21), t(15;17), inv(16) or young
age. The intermediate group consists of patients with
normal cytogenetics, +8, +21, +22 or -9q, while a com-
plex karyotype, -7, -5, MLL anomalies or FLT3-ITD (31)
correlate with poor prognosis. hEag1 expression was
often associated with an intermediate prognosis in 25 of
49 patients (51%). In 17 of 47 patients it correlated with
an unfavorable prognosis (36%, p = 0.66), while only 3
of 16 patients (19%) with a favorable prognosis profile
expressed hEag1. Chromosome 5 or 7 abnormalities
(n = 16) or multiple aberrations (n = 22) were often
Figure 1 hEag1 expression patterns in leukemia. A. Percentage of hEag1 positive patients as a function of cytological diagnosis. The
percentage of hEag1 positive samples in each subgroup is given on top of each bar pair. hEag1 expression was subtype dependent in AML.
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Table 1 Patient characteristics
Study population hEag1 positive hEag1 P-value
negative
No (%) 118 47 (40) 71
Gender, no. of males (%) 59 23 (50) 36 1.0
Age, years median (range) 49(1-89) 60 (1-86) 31 (1-89) <0.001***
Age groups, N (%) <0.001***
child (1-18 years) 37 5 (13) 32
adult (19-59 years) 38 18 (47) 20
elder (60-90 years) 43 23 (53) 20
FAB classification, N (%) 0.32
M0 7 2 (28) 5
M1 20 9 (45) 11
M2 25 14 (56) 11
M3 8 0 8
M4 19 10 (53) 9
M4Eo 6 0 6
M5 14 3 (21) 11
M6 5 3 (60) 2
M7 3 1 (33) 2
unclassified 11 5 (45) 6
Cytogenetic analysis, N (%) 0.11
normal 38 25 (66) 13
t (8;21) 7 3 (43) 4
inv (16) 6 0 6
t (15;17) 8 0 8
11q23 abnormalities 10 1 (10) 9
FLT3-ITD 5 4 (80) 1
chromosome 5 or 7 abnormalities 16 7 (44) 9
Trisomy 8 alone 6 2 (33) 4
other single abnormality 6 1 (17) 5
multiple abnormalities 22 9 (41) 13
unknown 14 4 10
Cytogenetic classification, no. (%) 0.66
Favorable 16 3 (19) 13
Intermediate 49 25 (51) 24
Unfavorable 47 17 (36) 30
Unknown 7 1 6
Stem cell transplantation 22 5 (23) 17 0.29
No stem cell transplantation 55 19 (34) 36
unknown 41 22 19
CR1 achieved, no. (%) 0.94
achieved 38 13 (34) 25
not achieved 27 9 (33) 18
unknown 53 24 29
Relapse, no. (%) 0.41
early relapse (within 6 months) 10 5 (50) 5
late relapse 32 11 (34) 21
no relapse within 3 years 25 3 (12) 22
unknown 24 13 11
Death, no. (%) 0.64
early death (within 6 months) 26 13 (50) 13
late death 32 14 (44) 18
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associated with hEag1 expression in 44% and 41%,
respectively. Interestingly, 4 of 5 patients (80%) with
FLT3-ITD were hEag1 positive.
The highest prevalence of hEag1 was reached in the
most frequent subtypes AML M2 and M4 with expres-
sion in more than half of the cases. Channel expression
significantly correlated with increasing age.
The hEag1 expression level in primary AML is a novel
independent predictive factor for a poor outcome
The frequent expression of hEag1 in AML suggests an
involvement of the channel in the pathophysiology of
this disease, which might be linked to patient outcome.
To test this hypothesis, statistical quantifications were
performed.
Relapse occurred significantly more frequently in
hEag1 positive patients both at early (less than 6
months, 26% vs. 10%) and late time points (58% vs.
44%). The median disease-free survival of hEag1 posi-
tive patients was strongly reduced compared to hEag1
negative patients (7 vs. 22 months, p = 0.0023). After 3
years, only 17% of hEag1-expressing patients were free
of disease, as compared to 41% of hEag1-negative
patients. In addition, the overall survival was strongly
reduced if leukemic cells expressed hEag1 (median OS,
10 vs. 52 months; p = 0.0019). Only 24% of the hEag1-
positive patients were alive after 3 years, compared to
54% of the hEag1-negative patients. The estimated
five-year survival rate was 15% for hEag1-positive and
48% for hEag1-negative patients (Fig. 4). This shows a
clear correlation of hEag1 expression with patient
outcome.
To determine if hEag1 expression adds predictive
value to age or karyotype alone, we used Cox regression
multivariate analysis. hEag1 expression levels, age and
karyotype are independent predictive parameters for the
overall survival of AML patients (p = 0.044, 0.058 and
0.057, respectively). In a positive/negative thresholded
analysis, without taking into account expression level in
the positive patients, channel expression did not add
predictive value over age alone in the elderly and mid-
age patients (older than 65 and 17.28 to 65 years; p =
0.59 and 0.44), but was still highly significant as a bad
prognostic factor in young patients (p = 0.0022).
In summary, we conclude that the expression level of
hEag1 strongly correlates with shorter survival expec-
tancy in AML and can be used as a novel independent
predictive factor, which eventually could be introduced
into routine prognosis analysis for advanced grouping
and therapy planning of AML patients.
Functional effects of hEag1 inhibition in vitro
Since hEag1 adds independent predictive value in AML,
it is conceivable that it might play a functional role in
leukemogenesis or disease maintenance. To address this
question we studied potential involvements of hEag1 in
the growth control, migration properties and differentia-
tion of AML cell lines and primary clinical samples.
Proliferation assays were performed with PLB-985, UT-
7, K562 and HEL cells. Different concentrations of the
Table 1: Patient characteristics (Continued)
Disease free survival (patient no.) 99 37 62 0.0023***
median, months 14 7 22
disease free at 3 years, no. (%) 28 5 (13) 23 (37)
Overall survival (patient no.) 99 37 62 0.0019***
median, months 24 10 52
alive at 3 years, no. (%) 35 6 (16) 29 (47)
alive at 5 years, no. (%) 21 2 (5) 19 (31)
Therapy protocol
AML-BFM-98 33 4 29
HD 98 A 15 4 11
AMLCG 12 5 7
AML-SG 06-04 5 4 1
AML-SG 07-04 5 3 2
HOVON-SAKK AML-43 6 4 2
supportive 9 6 3
unknown 34 16 18
Peripheral blood blasts, % median (range) 65 (0-100) 42 (0-95) 66 (2-100) 0.39
Bone marrow blasts, % median (range) 85 (0-100) 90 (25-98) 85 (0-100) 0.94
WBC, ×109/l median (range) 33.7 (0.9-400) 50.8 (2.6-222 32 (0.9-400) 0.76
The table shows the clinical characteristics of all analyzed patients. Percentages refer to the corresponding study population. hEag1 expression is correlated to
increased age, unfavorable prognosis, higher relapse rates and strongly shorter overall survival. FAB: French-American-British classification of AML; WBC: white
blood cell count; CR1: first complete remission.
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Figure 2 Expression of hEag1 in leukemia cell lines and primary AML cells. A: hEag1 mRNA levels determined by real-time PCR, expressed
as relative to that in UT-7 cells. B: hEag1 protein content in cell lines and primary cells from hEag1 positive patients measured by flow
cytometry. The background rightward shift induced by anti-hEag1 antibody mAb49 in the PCR-negative P2 cells was set as zero value. C: hEag1
siRNA treatment (lower panels) strongly diminished the fluorescence shift attributable to hEag1 expression in PLB-985 and K562 cells. The gray
peak indicates control secondary fluorescent antibody staining.
Agarwal et al. Molecular Cancer 2010, 9:18
http://www.molecular-cancer.com/content/9/1/18
Page 6 of 16
hEag1 inhibitors astemizole, imipramine and mAb56
were tested for inhibition of proliferation. None of the
inhibitors consistently affected HEL cell proliferation. In
contrast, the proliferation of PLB-985, UT-7 and K562
(Fig. 5) cells was strongly inhibited (up to 77% after 4
days, p < 0.05) in a dose-dependent manner by astemi-
zole (0.5-4 μM) or imipramine (5-20 μM). These con-
centrations correlate well with those described in other
cell types [21,23,25]. Among primary clinical samples,
only P3 and P4 (hEag1 positive) showed detectable pro-
liferation. Of these, the proliferation of P4 cells was
strongly inhibited by all inhibitors (virtually abolished
after three days, Fig. 5D)
Previous studies [26] described impairment of leuke-
mia cell proliferation by HERG inhibition. HERG is
abundantly expressed in K562 cells and in low amounts
in UT-7 cells. It is conceivable that part of the observed
effect is due to HERG blockade. This argument is not
applicable to PLB-985 or primary cultured cells, where
we did not detect any expression of HERG. To clarify
the extent of hEag1 implication in the regulation of pro-
liferation of these cell lines, we used the monoclonal
antibody mAb56, a very specific inhibitor of hEag1 that
does not modify HERG and even not hEag2 activity. 10
or 20 μg/mL mAb56 inhibited PLB-985 by 70%, UT-7
by 80% and K562 proliferation by 98% after 4 days (p <
0.05). The mAb56 abolished the proliferation of P4 pri-
mary cells.
Finally, knockdown of hEag1 expression by siRNA in
PLB-985 and K562 cells also resulted in up to 80%
diminished proliferation over 5 days. (hEag1 knockdown
by siRNA was not possible in UT-7 cells.) Representa-
tive proliferation curves are shown in Fig. 5. Effective
hEag1 knockdown by siRNA was confirmed by flow
cytometric detection of cells stained with anti-hEag1
mAb49 (see Fig. 2C). Altogether, our data suggest that
hEag1 is implicated in the regulation of leukemia cell
proliferation.
Proliferation inhibition can be a result of cell cycle
arrest. Such an effect has been described for the related
ion channel HERG, whose inhibition leads to cell arrest
at the G1/S transition [27]. To test a similar scenario
for hEag1, we analyzed cell cycle distribution after inhi-
bitor treatments. hEag1 inhibition did not consistently
affect the cell cycle distribution of these cell lines (Fig.
6A). Nevertheless, the mAb56 increased the fraction of
cells in the S phase in K562 and HEL cells significantly.
In primary cultured cells only G0-G1 populations could
be detected. hEag1 might be required for the transition
between S and M or for DNA synthesis itself as the
mAb56 increases the amount of cells in the S phase of
the cell cycle in K562 and HEL cells.
Apoptosis induction is a desirable therapeutic effect.
For K562 cells, an intense induction of apoptosis was
observed after treatment with imipramine and astemi-
zole up to 81% after 1 day (Fig. 6B). Increased apoptosis
Figure 3 hEag1 expression correlated to three age groups: 0-18, 19-59 and 60-89 years. With increasing age hEag1 expression became
more abundant.
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Figure 4 Shorter survival in hEag1 positive patients. Kaplan-Meier curves show the disease-free and overall survival of patients expressing
(black line) or not expressing (grey dashed line) hEag1. A significantly shorter disease-free (7 vs. 22 months, p = 0.0023) and overall survival (10
vs. 52 months, p = 0.0019) can be observed in hEag1 positive versus hEag1 negative patients.
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was not detected in other cell lines, nor was it induced
by siRNA or mAb56, indicating that the increased apop-
tosis is not solely due to hEag1 blockade. In primary
AML cells from one patient (P4) apoptosis and necrosis
was 2 times increased by 10 μg/mL mAb56 and 20 μM
imipramine (Fig. 6B).
We also tested the effects of hEag1 inhibiting agents
in combination with chemotherapeutic agents com-
monly used for AML induction therapy, cytarabine, eto-
poside, idarubicin and doxorubicin (Fig. 7). All drugs
(except cytarabine) induced some degree of caspase acti-
vation in all three cell-types tested, but the effects were
intense only in PLB-985 cells (Fig. 7). Apoptosis was
strongly increased over basal levels in PLB-985 cells
treated with etoposide, doxorubicin and idarubicin.
Combination of either of these drugs with astemizole or
mAb56 resulted in further increased apoptosis. Cytara-
bine alone was not able to induce apoptosis in PLB-985
cells, nor did it in combination with astemizole; how-
ever, combined with mAb56 antibody it induced caspase
activation. K562 cells were relatively resistant to apopto-
sis induction with any of the drug combinations,
although astemizole was still able to increase idarubicin
toxicity.
Migration is an important feature of malignant cells
and its therapeutic inhibition might be critical to avoid
Figure 5 Effects of hEag1 blockade on proliferation of leukemia cells in vitro. Proliferation inhibition of PLB-985 (A), UT-7 (B), K562 (C) and
primary cells (P4; D) treated with 20 μM imipramine (filled triangles), 4 μM astemizole (open triangles), 10 μg/mL monoclonal hEag1 antibody
mAb56 (filled circles) or 30 nM anti-hEag1 siRNA (open squares) is shown over 4 or 5 days as compared to control cells (open circles). (Mean ±
SEM).
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Figure 6 Cell cycle distribution and apoptosis in the presence of hEag1 inhibitors in vitro. A. The indicated cell lines were incubated with
4 μM astemizole (AST), 20 μM imipramine (IMI) or 10 μg/mL anti-hEag1 mAb56 for 2 days. Cell cycle phases were measured after staining with
propidium iodide by flow cytometry. Only mAb56 increased significantly the proportion of cells in the S phase in K562 and HEL cells. B. K-562
and primary P4 cells were incubated with 4 μM astemizole or mAb56 antibody for 2 days, respectively and apoptosis was measured by flow
cytometry. A clear increase in Annexin V fluorescence (apoptosis) was observed in both determinations.
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metastasis of solid tumors. To fully characterize the cap-
abilities of hEag1 expressing cells, we studied their
migration potential and the ability of channel inhibitors
to reduce cell migration. K562 and UT-7 cells did not
show migration in our experimental paradigm and were
therefore not further studied. HL-60 and PLB-958 cells
showed limited, although detectable migration, while
HEL cells showed much higher migration levels. Inhibi-
tion of hEag1 by imipramine and mAb56 (Fig. 8)
reduced the migration of HEL and PLB-985 cells up to
65%, indicating an implication of the channel activity in
this phenomenon. hEag1-positive primary AML cells
showed strong migration without any reduction due to
inhibitor treatments.
As transient hEag1 expression is important during dif-
ferentiation of other cell types like myoblasts, we tested
its possible involvement in hematopoietic differentiation.
We used the model cell line HL-60, which is arrested at
the promyelocytic stage, but can be terminally differen-
tiated over 6 days into granulocytes by retinoic acid.
Cell differentiation was shown by Giemsa stain of cell
nuclei and an increase of CD38 expression in flow cyto-
metry measurements. We determined hEag1 expression
every 2 h during differentiation but did not detect any
hEag1 expression at any time during the entire differen-
tiation process (data not shown).
Our functional analyses of AML cell lines and primary
AML specimens implicate a role of hEag1 in migration
and cell proliferation, without a clear cell cycle arrest.
Because hEag1 inhibitors are able to block proliferation
and migration they might be useful for therapeutic
approaches.
Discussion
The involvement of hEag1 potassium channels in leuke-
mias had not been systematically studied, although its
relevance for many solid tumors is well established. We
analyzed the prevalence and prognostic impact of hEag1
expression in 154 patients with newly diagnosed leuke-
mia with special focus on 118 AML patients. In solid
tumors, hEag1 is expressed in over 70% of carcinomas
and sarcomas [10,11]. Smith et al. [24] did not detect
hEag1 in CLL, and therefore we did not study CLL sam-
ples. In ALL we did not detect any hEag1 expression;
although the sample number was low. This might indi-
cate that hEag1 expression is not relevant in lymphatic
leukemias.
A completely different scenario applied for myeloid
leukemias. Although we detected hEag1 expression in
one third of the patients with CML, we did not perform
further statistical analyses due to the limited availability
of samples. We therefore concentrated on AML, where
we found an interesting subtype-dependent hEag1
expression, since one half of the cases of the most
Figure 7 Induction of apoptosis by chemotherapeutic drugs.
Apoptosis was measured through caspase activation and is
represented as relative increase with respect to basal apoptosis in
PLB-985 (A), K562 (B) and primary cultured P4 cells (C). Significant
increases were observed in PLB-985 cells. In this cell type,
Astemizole and mAb56 increased the efficacy of the drugs.
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common subtypes M2 and M4 expressed hEag1, and
Figure 8 Inhibition of the migration of cell lines in the presence of hEag1 inhibitors. HEL and PLB-985 cell migration was reduced by the
specific anti-hEag1 mAb56.
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this correlated with increasing age, higher relapse rates
and a significantly shorter overall survival.
Interestingly, 50% of MDS expressed hEag1. This
could represent a similar situation to the report by Far-
ias et al. [19] in cervix carcinoma, where they detected
hEag1 expression in cervix carcinomas and cervical
hyperplasias that are often pre-forms of carcinomas. If
this is also true for AML, hEag1 expression outside the
brain might be useful as an early marker for malignant
cell transformation, although such a far-reaching con-
clusion would require the support of prospective studies
in a large sample population.
66% of the patients with normal cytogenetic AML
expressed hEag1. These patients with a normal karyo-
type represent a very heterogeneous group with regard
to prognosis and therapy response. Several molecular
markers like FLT3-ITD, MLL, CEBPA (CCAAT/enhan-
cer binding protein) or BAALC (brain and acute leuke-
mia, cytoplasmic) further characterize some of these
patients but there is still highly unmet medical need for
other factors to establish a clear prognostic profile in
every individual patient [28,29]. It was therefore impor-
tant to determine if hEag1 expression in AML has prog-
nostic relevance. In other studies, hEag1 expression was
associated with an unfavorable outcome in sarcomas,
but no multivariate Cox regression analyses were per-
formed, so it is not know if hEag1 expression has any
predictive potential in sarcoma [11]. In our study, we
observed a clearly decreased survival in hEag1 expres-
sing patients. This could be due to higher expression
frequencies in elder patients, since children with AML
respond better to therapy than adults. However, multi-
variate Cox regression analysis determined an indepen-
dent predictive value for hEag1 expression (p = 0.044),
karyotype (p = 0.049), age (p = 0.058) and cytology (p =
0.057), while gender was not predictive (p = 0.20). The
median overall survival of 10 months of hEag1 overex-
pressing patients was strongly reduced compared to
hEag1 non-expressing patients with 52 months OS (p =
0.0019). The patient’s prognosis is important for thera-
peutic decisions like bone marrow transplantation,
which can prolong the survival or even cure the disease.
But it is accompanied with risky side effects that might
not be acceptable for patients who anyway have a good
prognosis with chemotherapeutic treatment. hEag1
could be used as an additional prognostic factor as it
significantly correlates with a bad prognosis. These find-
ings could justify a prospective study to evaluate the use
of hEag1 as predictive factor during routine clinical pro-
filing of newly diagnosed AML patients.
Finally, hEag1 expression has been proposed as the
basis of a potential new therapeutic target, due to its
restricted expression outside the central nervous system
and the effects of hEag1 inhibition on the proliferation
of several tumor cell types in vitro [11,23] and in vivo
[9,20]. We observed that hEag1 inhibition reduced the
proliferation of several AML cell lines. Most available
blockers of hEag1 are also effective inhibitors of other
channels and enzymes, some of which could be present
in the model cells used in this study. However, the
observation that the specific anti-hEag1 antibody
mAb56 and siRNA show similar strong inhibitory effects
as the tested drugs argues for an implication of hEag1 in
the proliferation of leukemia cells. The limited number
of cell lines expressing hEag1 precluded establishing a
reliable correlation between expression levels and
impact of channel inhibition on cell proliferation. We
could not perform experiments with hEag1 overexpres-
sion because we did not achieve reliable transfection
efficiencies on leukemia cell lines, either by lipofection
or nucleofection, even if control vectors could be suc-
cessfully transfected, which might indicate deleterious
effects of hEag1 overexpression on the cells
One of the primary AML cell preparations with the
highest hEag1 content showed comparable behavior to
established cell lines. The inhibition achieved through
hEag1 inhibitors was even faster and more intense than
in cell lines. These results prompt further experiments to
establish if leukemias with a particular expression pattern
might be suitable targets for anti- Eag1 strategies.
Other members of the Eag K+-channel subfamily have
been implicated in the pathophysiology of leukemias.
HERG channels have been described to be up-regulated in
a wide spectrum of hematopoietic malignancies like AML
(~70%), CML, ALL or lymphomas, while it is not
expressed during physiological hematopoietic develop-
ment or in normal peripheral blood cells [30]. HERG
channels regulate leukemia blast proliferation, improve
AML cell migration and invasiveness and correlate with
higher relapse and shorter survival [26,31]. The inhibition
of HERG reduces leukemia cell growth and arrests cells at
the G1/S transition phase [27]. Therefore, HERG channels
could have broader therapeutic applications in leukemia
than hEag1, but its ubiquitous expression throughout the
body and its crucial role in cardiac repolarization are chal-
lenging problems for a HERG-based therapy because
severe side effects like fatal arrhythmias can occur [32].
In K562 cells, which express high levels of both hEag1
and HERG, we observed a dramatic induction of apop-
tosis induced by both imipramine and astemizole. It is
tempting to speculate that simultaneous inhibition of
hEag1 and HERG in those cell types expressing both
channels could be an efficacious therapeutic approach.
In combination with routinely used induction thera-
peutics, the hEag1 blockers astemizole and mAb56 were
able to increase the apoptotic response in PLB-985 cells.
This could be advantageous by increasing leukemia
responsiveness during the critically important induction
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therapy. However, this effect was cell type specific, indi-
cating that accurate profiling of the AML cells, together
with complete toxicity profiles of such drug combina-
tions will be required and have to be critically evaluated
in primary cells and animal models.
An increased migration capability is one important
sign of malignancy. hEag1 expressing leukemia cell lines
show higher migration rates than non-expressing ones.
hEag1 inhibitors were able to reduce cell migration. In
the context of a therapeutic usage those inhibitors
might be important that are able to prevent several fea-
tures of malignancy like proliferation, migration or func-
tional properties of these transformed cells.
The potential of hEag1 inhibitors for a usage in leuke-
mia treatment has to be carefully further analyzed in
primary cells in vitro and mouse models in vivo.
Conclusions
We showed that hEag1 is indeed frequently expressed in
myeloid leukemia and MDS. In AML it is expressed
with high frequency in the most common subtypes and
it correlates with increasing age, higher relapse rates
and a significantly shorter overall survival. Statistical
analyses revealed hEag1 as an independent predictive
factor for a worse outcome. Functional studies showed
the potential of hEag1 inhibitors to reduce proliferation
and migration of AML cell lines and primary cells. Our
data suggest a potential for hEag1 as tumor marker for
early tumor screening of hematopoietic disorders, as
prognostic factor in certain AML types and as therapeu-
tic target of specific inhibitors in the treatment of AML.
Antibody-labeled aggressive therapy with radionuclides
or toxic molecules could act locally and highly effi-
ciently. More detailed analysis will be performed to




RNA or frozen cells isolated from the peripheral blood
or bone marrow from patients with newly diagnosed
AML were obtained from the hematology department of
the University Medicine Göttingen. Molecular genetic
analyses of patient’s blood samples were performed with
their informed consent and upon approval by the local
ethics committee. Patient details are summarized in
Table 1. The median follow up was 4.2 years (range
0.75-7.2 years). Treatment regimes are summarized in
Additional File 1.
Definition of response, relapse and end points
Complete remission (CR) was defined by ≤ 5% bone
marrow blasts, neutrophile counts ≥ 1000/μL, platelets
≥ 100,000/μL and lack of extramedullar disease.
Cytogenetic remission was defined by normal cytoge-
netics, and molecular remission by negative molecular
studies. Disease-free survival (DFS) was measured from
CR to relapse. Overall survival (OS) was defined as
time from diagnosis to death irrespective of the cause.
Living patients were censored at the date of last fol-
low-up.
RNA isolation, cDNA synthesis and real time PCR
Mononuclear cells were isolated from peripheral blood
or bone marrow by density centrifugation over a Ficoll
gradient and RNA was isolated from the buffy coat [33].
Either lysates from frozen cells or total RNA was
obtained. Total RNA was isolated from 5 × 106 cells
using the RNeasy mini isolation kit for animal cells
(Qiagen, Hilden, Germany) with additional DNAse treat-
ment according to the manufacturer’s protocol. cDNA
synthesis and real time PCR were performed as pre-
viously described [10]. Quantification was performed
using the ΔΔCT method (cell lines) or after Pfaffl [34].
Cell culture
The human myeloid leukemia cell lines HL-60 (AML
M2, DSMZ ACC 3, Braunschweig, Germany), K562
(CML in blast crisis, ACC 10), PLB-985 (AML M4,
ACC 139; this is a subclone of HL-60 cells), HEL
(AML M6, ACC 11), CMK (AML M7, ACC 392) and
KASUMI-1 (AML M2, ACC 220) were cultured in
RPMI1640 medium with 10% fetal calf serum (Invitro-
gen, Karlsruhe, Germany). UT-7 cells (AML M7, ACC
137) were cultured in alpha-MEM medium with 20%
FCS and 5 ng/mL GM-CSF. Cells were maintained at
37°C and 5% CO2 in a humidified atmosphere.
Peripheral blood from 4 patients was obtained at the
time of initial diagnosis prior to therapy. Primary leuke-
mic blasts were isolated by density centrifugation for 30
min at 800 × g (Lymphoprep, Axis-Shield, Oslo, Nor-
way) Cells from the buffy coat were washed three times
with PBS and cultured in RPMI1640 medium supple-
mented with 20% FCS, 1% pyruvate (Sigma-Aldrich,
Steinheim, Germany), 1% insulin-transferrin-selenium
(ScienCell, Carlsbad, CA) and 1% penicillin/streptomy-
cin (Invitrogen).
Differentiation of HL-60 cells into granulocytes was
induced with 2 μM retinoic acid over 6 days [35,36].
During differentiation, samples were obtained every 2 h
and analyzed for hEag1 expression up to day 6. Differen-
tiation was monitored by successive Giemsa stains, and
confirmed after 6 days by flow cytometry, through up-
regulation of CD38 [37].
To measure apoptosis under induction drugs, 2 ×
105 PLB-985, K562 and primary P4 cells in 24-well
plates were incubated with 2 μM idarubicin, 20 μM
etoposide, 6 μM cytarabine or 4 μM doxorubicin either
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alone or in combination with 4 μM astemizole or 10
μg/mL mAb56 for 24 h. Apoptosis was assessed with
the Caspase-Glo 3/7 Assay system (Promega) measur-
ing luciferase-induced luminescence in a 96-well plate
reader according to the manufacturer’s instructions.
Proliferation assays
PLB-985, UT-7, K562, HEL or primary clinical cells were
seeded in 96-well plates (2,000 cells/well or 10,000 pri-
mary cells/well) and cultured with different concentra-
tions of astemizole (0.5-4 μM), imipramine (5-20 μM) or
mAb56 (5-20 μg/mL) for up to 5 days. These inhibitor
concentrations are below non-specific cytotoxic doses (5
μM astemizole [21] and 50 μM imipramine [22]). The
functional monoclonal anti-hEag1 antibody mAb56 (10
μg/mL) was used as hEag1-specific blocker because it
does not affect HERG or hEag2 [9]. Cell proliferation was
measured every 24 h by Alamar Blue (Invitrogen) fluores-
cence after 2 h incubation with the dye in a 1420 Victor2
Multilabel Counter (Ex 544, Em 590 nm; Wallac-Perkin-
Elmer, Waltham, MA). The relative proliferation was
normalized to control cell growth without inhibitor.
siRNA
hEag1 silencing was performed using 30 nM siRNA
(sense: r(CAG CCA UCU UGG UCC CUU A)dTdT,
antisense: r(UAA GGG ACC AAG AUG GCU G)
dTdA). Transfection was performed by nucleofection
(Amaxa, Lonza, Cologne, Germany) according to the
manufactures recommendations with 2 × 106 K562 or
PLB-985. No transfection was achieved in UT-7 cells.
Commercial non-targeting scrambled siRNA (Ambion,
Darmstadt, Germany) and anti-GAPDH siRNA were
used as negative and positive control, respectively. RNA
and protein knockdown after 2 days was confirmed by
real-time PCR and flow cytometry.
Migration analysis
3 × 105 cells were seeded in the upper reservoir of 24-
well Boyden chambers in serum-free medium. The
lower compartment contained medium with 20% FCS.
After 24 h incubation at 37°C, cells in the lower cham-
ber were centrifuged, resuspended in 10 μL medium
and counted in a Neubauer chamber.
Flow cytometry
For hEag1 protein analysis, cells were fixed for 10 min in
10% formalin, quenched with 100 mM glycine, permeabi-
lized for 5 min in 0.1% Triton-X100 and incubated over-
night in blocking buffer (0.2% gelatin in PBS). The
primary antihEag1 antibody (mAb49) was used at a con-
centration of 1.3 μg/mL for 1.5 h. Cells were washed three
times with blocking buffer and incubated in 1 μg/mL
AlexaFluor 488-labeled secondary antibody for 2 h. The
whole procedure was performed at 4°C. Finally, cells were
washed four times, resuspended in PBS and measured in a
BD FACSAria flow cytometer (Becton Dickinson, Heidel-
berg, Germany). Only single viable cells (as determined by
forward-sideward scatter) were gated and further analyzed.
Apoptosis analysis was performed using Annexin V-
AlexaFluor 488 or 680 (Vybrant Apoptosis Assay Kit #2,
Invitrogen) and 100 μg/mL propidium iodide according
to the manufacturer’s instructions.
For cell cycle determination, cells were washed once
with PBS and incubated for 15 min in 50 μg/mL propi-
dium iodide, 0.3% saponine and 100 U/mL RNAse A in
PBS at 4°C. Flow cytometry measurements were per-
formed within 1 hour, measuring less than 200 cells/sec-
ond. Data were analyzed with FlowJo software (TreeStar,
Ashland, OR).
Differentiated HL-60 cells were stained with 25 μg/mL
anti-CD38 antibody per 106 cells in 100 μL final volume.
After 20 min incubation at room temperature, cells were
washed and resuspended in PBS.
Statistical analysis
Estimated probabilities of OS and DFS and time-to-
event curves were constructed according to the Kaplan-
Meier method and were compared with the log-rank c2
test. Group data are expressed as mean ± SD. Student’s
t-test was used for single comparison at 95% confidence.
Prognostic factors were examined by multivariate Cox
proportional Hazards Survival Regression analysis [38].
Patients with CML or MDS were not statistically ana-
lyzed because of small sample numbers.
Additional file 1: Therapy protocols. The table summarizes the
therapeutic regimes of patients studied.
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